🔗 Share this article

As the US proceeds with historic revisions to its vaccination guidelines, a particular individual has surfaced in a surprising turn: Dr. Tracy Beth Høeg, a US-based sports medicine doctor and public health researcher who rose to prominence by casting doubt on Covid shots during the pandemic and has concentrated on potential fatalities following COVID-19 vaccination in her brief tenure at the US Food and Drug Administration (FDA).

Planned Overhauls to Pediatric Immunization Schedule

Health officials had intended to announce major changes to the childhood vaccination calendar recently, synchronizing the US with Denmark’s immunization schedule, sources say – a significant shift that would place the US at odds with much of the global community with little proof for benefit. This reveal has been pushed back until the new year.

In place of the director of the vaccine center, Dr. Høeg is set to address the audience at the gathering. She was recently named acting director of the FDA’s drug evaluation center, the fifth appointee to run the division this calendar year.

A New Direction at the Agency

Høeg's temporary position could signify a tighter collaboration between the pharmaceutical and biologics branches as Høeg and Dr. Prasad consolidate power at the regulatory agency – and it suggests a renewed priority upon rolling back long-standing immunizations at the FDA.

The new acting director has frequently advocated for discontinuing certain childhood immunization guidelines in the US in order to be more like Denmark's approach, a nation with universal health coverage and a citizenry approximately the population of Wisconsin’s.

In her initial public appearances, she has persisted in emphasizing on immunizations – typically the purview of Dr. Prasad, director of the FDA’s CBER – as opposed to drug regulation.

Doubts Over Qualifications

Høeg has little discernible experience in pharmaceutical research, oversight or administrative roles, which has been standard for previous leaders of the CBER. She has worked at the FDA as a top consultant to the commissioner and the vaccine center since earlier this year.

“She appears not to have the requisite experience” for overseeing the CDER, stated a neurologist and psychiatrist. “She has not conducted a randomized controlled trial. She has no expertise in running a sizeable institution. She lacks background in pharmaceutical oversight.”

Former heads of CBER would “grasp laws and regulations and the science of pharmaceutical innovation”, commented Dr. Janet Woodcock. “Frankly, she doesn’t have the type of experience that previous people who led the center have had.”

The drug center has an immense portfolio at the FDA, the former commissioner stated.

“The public just pays attention on the novel medication approvals, but the generic program clears numerous generic drugs. There’s a biosimilars division, OTC medication office and so forth, and every single one have to be managed,” she explained. “The area you overlook, that is the part that I always told people is going to bite you.”

Additionally, a significant leadership element to the job, which oversees more than 5,000 staff members. “It’s a enormous administrative position, if you perform it correctly,” the former official said.

Agency Reaction and Contentious Programs

When asked about concerns about Høeg’s qualifications and whether this selection indicates more teamwork among agency officials on vaccines, a spokesperson stated that the “concerns stem from incorrect premises”.

“This background aligns with the responsibilities of her role,” the representative said, citing the months Høeg spent advising the FDA commissioner on “medication safety and approval science, including computational safety modeling and vaccine surveillance”.

As acting director, Dr. Høeg inherits the agency head's recently launched expedited review system, a disputed expedited therapy clearance system that allegedly worried her preceding directors. “How are these medications being chosen for this expedited pathway? Who takes the decisions?” Howard questioned. “There’s a lot of secrecy going on at the agency right now.”

Overall, he remarked, “the FDA seems to be moving towards laxer regulations of all drugs, with the exception of vaccines.”

Public History on Vaccines

Concerning immunizations, Dr. Høeg has a more established, if problematic, track record, some experts said. She published a analysis using unverified public submissions to assess the rate of myocarditis after Covid immunization. She consulted for the Florida chief medical officer Dr. Joseph Ladapo, who was said to have modified findings to imply Covid vaccinations are riskier than they are.

Among her “wish list” for the current federal leadership featured revising rules for recently developed shots and ending “non-essential” immunizations, she stated post-election on a podcast. At the FDA, Høeg has reportedly proposed preventing adolescent males from receiving COVID-19 vaccines.

“She is an all-around true believer who starts off with her preconceived notions and tailors the evidence to retrofit the evidence in a very disingenuous, fraudulent manner,” Howard stated.

Consolidating Power and a “Campaign of Retribution”

Høeg joined fellow skeptics, {like|